Zydus Lifesciences Limited (NSE:ZYDUSLIFE)

India flag India · Delayed Price · Currency is INR
887.95
+7.30 (0.83%)
May 7, 2025, 3:30 PM IST
-13.01%
Market Cap 891.67B
Revenue (ttm) 222.47B
Net Income (ttm) 45.37B
Shares Out 1.01B
EPS (ttm) 45.03
PE Ratio 19.69
Forward PE 19.08
Dividend 3.00 (0.34%)
Ex-Dividend Date Jul 26, 2024
Volume 819,308
Average Volume 2,005,657
Open 863.20
Previous Close 880.65
Day's Range 863.20 - 889.15
52-Week Range 795.00 - 1,324.30
Beta 0.47
RSI 52.04
Earnings Date May 16, 2025

About Zydus Lifesciences

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers finished dosage human formulations, such as generics; branded generics; specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; animal healthcare products; and products in the therapeutic areas of pain management... [Read more]

Sector Healthcare
Founded 1952
Employees 26,921
Stock Exchange National Stock Exchange of India
Ticker Symbol ZYDUSLIFE
Full Company Profile

Financial Performance

In 2023, Zydus Lifesciences's revenue was 195.47 billion, an increase of 13.40% compared to the previous year's 172.37 billion. Earnings were 38.60 billion, an increase of 96.88%.

Financial Statements

News

Zydus gets USFDA final approval for Niacin Extended-Release Tablets

Zydus Lifesciences Limited, along with its subsidiaries and affiliates (collectively referred to as “Zydus”), has received final approval from the United States Food and Drug Administration (USFDA) to...

7 days ago - Business Upturn

Stocks to watch on April 28: Force Motors, Jayaswal Neco, NRB Bearings, Titan, Reliance Industries, Zydus Lifesciences in focus

Stocks are likely to see active trading on April 28 after several companies reported their Q4FY25 earnings and corporate announcements. Here’s a quick look: Positive developments: Jayaswal Neco report...

9 days ago - Business Upturn

Zydus Lifesciences receives 6 observations from USFDA for Gujarat API unit

India-Business News: Zydus Lifesciences on Saturday said it received six observations from the US Food and Drug Administration (USFDA) following a surveillance inspection .

11 days ago - The Times of India

Zydus Lifesciences receives 6 observations in USFDA inspection at API unit in Dabhasa, Gujarat

Zydus Lifesciences has recently undergone a USFDA surveillance inspection at its Active Pharmaceutical Ingredient (API) manufacturing unit located in Dabhasa, Gujarat. The inspection, conducted from A...

11 days ago - Business Upturn

Zydus Medtech, Braile Biomedica sign global licensing pact to commercialise advanced TAVI technology

Zydus MedTech Private Limited, a wholly owned subsidiary of Zydus Lifesciences, has entered into a strategic global licensing agreement with Brazil-based Braile Biomedica to commercialise its cutting-...

20 days ago - Business Upturn

Zydus Lifesciences confirms losing US patent case to Astellas in mirabegron litigation

Zydus Lifesciences Ltd announced that the United States District Court for the District of Delaware has ruled in favor of Astellas Pharma Inc., upholding the validity of the Japanese drugmaker’s US Pa...

20 days ago - Business Upturn

Zydus Lifesciences shareholder commitments in tender offer for Amplitude Surgical

Zydus Lifesciences Limited has announced the execution of undertakings from seven shareholders to tender a total of 2,236,911 shares of Amplitude Surgical SA. These shares represent approximately 4.7%...

20 days ago - Business Upturn

Zydus down 5%, Lupin down nearly 4% as US court orders withdrawal of Myrbetriq drug

Shares of Zydus Lifesciences and Lupin plunged sharply on April 16 after both companies lost a patent litigation case related to the bladder treatment drug Myrbetriq in the United States. The US Feder...

21 days ago - Business Upturn

Zydus Lifesciences shares drop over 2.5% after losing Myrbetriq patent case in US

Shares of Zydus Lifesciences Ltd fell sharply by 2.63% to ₹859.95 during Tuesday’s trade following a major legal setback in the US. The stock dropped from a previous close of ₹883.15, reacting negativ...

21 days ago - Business Upturn

Stocks to watch today: Zydus, Aurobindo, HCL Tech, Tata Power, Indian Hotels, Cyient in focus on expansion and global deals

Stocks of several companies are expected to remain in the spotlight today following a series of announcements related to international expansion, regulatory approvals, and strategic partnerships. Zydu...

23 days ago - Business Upturn

Top Stocks to watch on April 15: Ircon, Zydus, Ashoka Buildcon, Tata Power, Macrotech, Cyient in focus as markets reopen after long weekend

Indian stock markets reopen after the Monday holiday (April 14) for Dr. Baba Saheb Ambedkar Jayanti. Here are the key stocks to watch: Ircon International Secured a Letter of Acceptance worth ₹127 cro...

23 days ago - Business Upturn

Zydus Lifesciences receives USFDA approval for Jaythari (Deflazacort) Tablets across four strengths

Zydus Lifesciences Limited has announced that it has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market its Jaythari® (Deflazacort) tablets i...

26 days ago - Business Upturn

Pharma Stocks Falls: Aurobindo Pharma slips 2%, Lupin down 2%, Divi’s Labs falls 3% as Trump reiterates tariffs on pharmaceuticals ‘soon’

Indian pharmaceutical stocks declined in early trade on Wednesday following renewed concerns over potential U.S. import tariffs. At 9:36 AM, Aurobindo Pharma shares were down 2% to ₹1,073.15, Dr. Redd...

4 weeks ago - Business Upturn

Zydus Lifesciences shares fall nearly 7% as Trump signals potential pharma tariffs

Shares of Zydus Lifesciences Ltd declined 6.92% to ₹839.50 on Friday, falling ₹62.40 from the previous close of ₹901.90, as concerns escalated over the potential imposition of U.S. tariffs on pharmace...

4 weeks ago - Business Upturn

Zydus Lifesciences shares jump 5.25% as U.S. spares pharma exports from 26% tariff

Shares of Zydus Lifesciences Ltd surged 5.25% to ₹937.95 on April 3, emerging as one of the top gainers in early trade, after U.S. President Donald Trump’s reciprocal tariff policy excluded pharmaceut...

4 weeks ago - Business Upturn

Top stocks to buy today: Stock recommendations for March 21, 2025

Stock market recommendations: Bajaj Broking Research recommends Zydus Lifesciences and National Aluminium stocks for today. It expects Nifty to move towards 23,500 levels and sees Bank Nifty heading t...

6 weeks ago - The Times of India

Zydus shares nearly jump 3% on USFDA approval for Apalutamide Tablets

Zydus Lifesciences Ltd saw nearly 3% surge in its stock price after securing final approval from the U.S. Food and Drug Administration (USFDA) to manufacture and market Apalutamide Tablets, 60 mg, in ...

7 weeks ago - Business Upturn

Zydus receives U.S. FDA nod for 60 mg Apalutamide Tablets

Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Apalutamide Tablets, 60 mg (Erleada® Tablets, 60 mg) in the...

7 weeks ago - Business Upturn

Zydus Lifesciences shares up 2% as USFDA grants approval for Eluxadoline tablets

Shares of Zydus Lifesciences Ltd (NSE:ZYDU) surged 2% after the company received final approval from the U.S. Food and Drug Administration (USFDA) to manufacture and market Eluxadoline Tablets (75 mg ...

7 weeks ago - Business Upturn

Top stocks to watch today, March 17: IndusInd Bank, Ola Electric, Tata Motors, Zydus Lifesciences and more

The Indian stock markets resume trading on March 17 after a three-day break, following a weak closing in the previous session. On March 13, the S&P BSE Sensex fell by 200.85 points to settle at 73,828...

7 weeks ago - Business Upturn

Zydus Lifesciences’ Ankleshwar API unit clears USFDA inspection with zero observations

Zydus Lifesciences Ltd announced that the US Food and Drug Administration (USFDA) has successfully concluded a surveillance inspection at its Active Pharmaceutical Ingredient (API) Unit 1 in Ankleshwa...

7 weeks ago - Business Upturn

Zydus receives USFDA approval for Methenamine Hippurate Tablets USP, 1 gram

Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Methenamine Hippurate Tablets USP, 1 gram (generic version ...

2 months ago - Business Upturn

Zydus Life in negotiations to buy French medtech firm

Zydus Lifesciences announced it is negotiating to acquire a majority stake in French medtech firm Amplitude Surgical for approximately Rs 2,500 crore. The acquisition aims to boost Zydus's global medt...

2 months ago - The Times of India

Zydus Lifesciences to acquire 85.6% stake in Amplitude Surgical SA for €256.8 million

Zydus Lifesciences Limited has announced its acquisition of an 85.6% controlling stake in Amplitude Surgical SA, a leading French MedTech company specializing in orthopedic solutions. This strategic m...

2 months ago - Business Upturn

Zydus gets USFDA final approval for Ketoconazole Shampoo, 2%

Zydus Lifesciences Limited has secured final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Ketoconazole Shampoo, 2% (a generic version of Nizoral® Sham...

2 months ago - Business Upturn